Adolescent females with sickle cell disease face unique challenges related to menstruation, contraception, and reproduction. Not only does pregnancy pose higher maternal morbidity and mortality risks in these patients [1], but hydroxyurea, a commonly used treatment for the disease is teratogenic [2].